Oragenics, Inc.

180 articles with Oragenics, Inc.

• Oragenics Awarded a $250,000 Grant from the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics.

  10/4/2021

  Oragenics, Inc. today announced that it was awarded a small business innovation research grant in the amount of $250,000 (“Computer-aided Design for Improved Lantibiotics” R41GM136034) for the Company’s continued research and development of lantibiotics, including its collaborative program with the Biomolecular Sciences Institute at Florida International University

• Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate

  9/15/2021

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced the initiation of a study to evaluate the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate in a hamster challenge study.

• Oragenics’ SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice with Intramuscular and Intranasal Adjuvants

  8/30/2021

  Oragenics, Inc. announces that the stabilized pre-fusion spike protein trimer produced by its Canadian collaborator and licensed by the Company from the National Institutes of Health (NIH) generates neutralizing antibodies in mice after immunization against SARS-CoV-2, when administered with several novel intramuscular and intranasal adjuvants.

• Oragenics Announces Postponement of Annual Meeting of Shareholders

  8/24/2021

  Oragenics, Inc. today announced the Company’s reconvened annual meeting of shareholders, on August 23, 2021 at 4:00 p.m. was adjourned due to a lack of quorum.

• Oragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines

  7/27/2021

  Oragenics, Inc. announced it has entered into a licensing agreement with the National Research Council of Canada that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants.

• Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

  7/1/2021

  Oragenics, Inc. announced that the Company’s annual meeting of shareholders, on June 30, 2021, at 9:00 a.m. was convened and adjourned, without any business being conducted, due to lack of the required quorum.

• Oragenics Issues Letter to Shareholders

  5/18/2021

  Executive Chairman Affirms Company Direction with Commitment to Speedy Execution of Business Strategy Highlights Deep Bench Strength Among Management, Board and Advisors in Vaccine Development and in Life Sciences

• Oragenics Announce Changes in Management and Board of Directors

  5/3/2021

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced that on May 2, 2021, Dr. Alan Joslyn resigned as Chief Executive Officer, President and director of Oragenics, Inc. to pursue other opportunities.

• Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 Vaccine

  3/9/2021

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced it has entered into a material transfer agreement with Biodextris Inc. for the use of three intranasal mucosal adjuvants in the Company’s Terra CoV-2 vaccine against COVID-19. Adjuvants are added to vaccines to enhance their immunogenicity. BDX100, BDX300 and BDX301 are proteosome-based adjuvants comprised of proteins and lipopolysaccharides

• Oragenics to Participate in Two Investment Conferences During March

  3/8/2021

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), today announced that Alan Joslyn, Ph.D., President and Chief Executive Officer of Oragenics, will participate in two virtual investment conferences during the month of March, as follows: The H.C. Wainwright Global Life Sciences Virtual Conference with one-on-one meetings being held March 9-10, 2021

• Oragenics Announces Recent Capital Raise and Warrant Exercises Totaling $21.9 Million and the Redemption of Its Series C Preferred Stock

  2/12/2021

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced it has raised approximately $20 million from the sale of common stock through a sales agreement with A.G.P./Alliance Global Partners for an “at-the-market” facility. In addition, the Company also received approximately $1.9 million from the exercise of common stock warrants.

• SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective Immunity in Mice

  2/2/2021

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announces that the stabilized pre-fusion spike protein CoV-2 S-2P created by the National Institutes of Health (“NIH”) and licensed by the Company demonstrates protective immunity in immunized mice challenged with mouse-adapted SARS-CoV-2 virus.

• Oragenics Issues Letter to Stockholders

  1/14/2021

  Oragenics, Inc. (NYSE American: OGEN) today issued the following letter to stockholders from its President and Chief Executive Officer, Alan Joslyn, Ph.D.: To My Fellow Stockholders, With so much encouraging news recently around COVID-19 vaccine development, this is an excellent time to update

• Oragenics Enters Into Material Transfer Agreement With Adjuvance Technologies for COVID-19 Vaccine Adjuvant

  1/7/2021

  Oragenics, Inc. announced entering into a material transfer agreement with Adjuvance Technologies Inc. for use of the adjuvant TQL1055 in the Company’s Terra CoV-2 vaccine against COVID-19.

• Oragenics, Inc. Announces $6.5 Million Registered Direct Offering

  12/24/2020

  Oragenics, Inc., a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, announced it has entered into definitive agreements with investors for the purchase and sale of 14,444,444 shares of its common stock at a purchase price of $0.45 per share in a registered direct offering.

• Oragenics Announces Closing of $6.0 Million Underwritten Public Offering

  11/24/2020

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, today announced, the closing of its previously announced underwritten public offering of 14,189,189 shares of common stock at a price to the public of $0.37 per share. Oragenics expects to receive gross proceeds of approximately $6.0 milli

• Oragenics Prices $5.25 Million Common Stock Offering - Nov 20, 2020

  11/20/2020

  Oragenics, Inc., a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, announced the pricing of an underwritten public offering of 14,189,189 shares of its common stock at a price to the public of $0.37 per share.

• Organics Announces Proposed Underwritten Public Offering - Nov 19, 2020

  11/19/2020

  Oragenics, Inc. a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, announced that it has commenced a proposed underwritten public offering of common stock of the Company.

• FDA Broadly Supports Oragenics’ Pre-IND Development Program for its SARS-CoV-2 Vaccine

  10/6/2020

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced receipt of feedback to its Type B Pre-IND Meeting Request from the U.S. Food and Drug Administration (“FDA”) that it is in broad agreement with the Company’s planned approach to clinical development of its SARS-CoV-2 vaccine, Terra CoV-2. As a r

• Oragenics Provides an Update on Funding for its SARS-CoV-2 Vaccine

  9/28/2020

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) provides an update on U.S. federal government and other funding options the Company is pursuing in order to advance its SARS-CoV-2 vaccine, Terra CoV-2. Oragenics has been informed by the Biomedical Advanced Research and Development Authority (“BARDA”) of BARDA’s determination not to enter into negotiation with the Company. While BARDA noted the Com